ReviewJournal of viral hepatitis2009
GB virus type C interactions with HIV: the role of envelope glycoproteins.
Review in Journal of viral hepatitis, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Pooled it
- Design and optimization of a multiplex real-time PCR assay for detection of Hepatitis C virus (HCV), Human immunodeficiency virus-1 (HIV-1) and Human hepegivirus-1 (HHpgV-1).Gastroenterology and hepatology from bed to bench · 2025Article
- Review of human pegivirus: Prevalence, transmission, pathogenesis, and clinical implication.Virulence · 2022Review
- A Case of Persistent Human Pegivirus Infection in Two Separate Pregnancies of a Woman.Microorganisms · 2022Article
- The Second Human Pegivirus, a Non-Pathogenic RNA Virus with Low Prevalence and Minimal Genetic Diversity.Viruses · 2022Review
- Clinical and molecular aspects of human pegiviruses in the interaction host and infectious agent.Virology journal · 2022Review
- Human pegivirus infection after transplant: Is there an impact?World journal of transplantation · 2022Review
- Human Pegivirus Type 1: A Common Human Virus That Is Beneficial in Immune-Mediated Disease?Frontiers in immunology · 2022Review
- Exploring the Diversity of the Human Blood Virome.Viruses · 2021Article
- Human pegivirus 1 in Cabo Verde: prevalence and genotypic distribution among HIV-infected individuals.Archives of virology · 2021Article
- Exploring Viral Interference Using Peptides: Molecular Determinants of HIV-1 Inhibition by a Peptide Derived from Human Pegivirus-1 Envelope Protein E2.ChemMedChem · 2021Article
- Deep viral blood metagenomics reveals extensive anellovirus diversity in healthy humans.Scientific reports · 2021Article
- Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteers.Virology journal · 2021Article
- In Vitro Comparison of the Internal Ribosomal Entry Site Activity from Rodent Hepacivirus and Pegivirus and Construction of Pseudoparticles.Advances in virology · 2021Article
- Human pegivirus (HPgV, GBV-C) RNA in volunteer blood donors from a public hemotherapy service in Northern Brazil.Virology journal · 2020Article
- The Role of Emerging and Neglected Viruses in the Etiology of Hepatitis.Current infectious disease reports · 2019Review
- Whole-genome sequencing of human Pegivirus variant from an Egyptian patient co-infected with hepatitis C virus: a case report.Virology journal · 2019Article
- A Caulobacter crescentus Microbicide Protects from Vaginal Infection with HIV-1Journal of virology · 2019Article
- Genetic variability of porcine pegivirus in pigs from Europe and China and insights into tissue tropism.Scientific reports · 2019Article
- Molecular and Clinical Profiles of Human Pegivirus Type 1 Infection in Individuals Living with HIV-1 in the Extreme South of Brazil.BioMed research international · 2019Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
GB virus C/hepatitis G virus (GBV-C/HGV) is the most closely related human virus to hepatitis C virus (HCV). GBV-C is lymphotropic and not associated with any known disease, although it is associated with improved survival in HIV-infected individuals. In peripheral blood mononuclear cells, GBV-C induces the release of soluble ligands for HIV entry receptors (RANTES, MIP-1a, MIP-1b and SDF-1), suggesting that GBV-C may interact with lymphocytes to induce a chemokine and/or cytokine milieu that is inhibitory to HIV infection. Expression of GBV-C envelope glycoprotein E2 in CD4+ T cells or addition of recombinant E2 to CD4 cells recapitulates the HIV inhibition seen with GBV-C infection. Like HCV E2, GBV-C E2 is predicted to be post-translationally processed in the endoplasmic reticulum and is involved with cell binding. The C-termini of GBV-C E1 and E2 proteins contain predicted transmembrane domains sharing features with HCV TM domains. To date, cellular receptor(s) for GBV-C E2 have not been identified. GBV-C E2-mediated HIV inhibition is dose-dependent and HIV replication is blocked at the binding and/or entry step. In addition, a putative GBV-C E2 fusion peptide interferes with HIV gp41 peptide oligomerization required for HIV-1 fusion, further suggesting that GBV-C E2 may inhibit HIV entry. Additional work is needed to identify the GBV-C E2 cellular receptor, characterize GBV-C E2 domains responsible for HIV inhibition, and to examine GBV-C E2-mediated fusion in the context of the entire envelope protein or viral-particles. Understanding the mechanisms of action may identify novel approaches to HIV therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.